Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.
The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.
The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Putting together the brightest minds involved in basic science, drug development, medical practice and commercialization to develop new cures in the most rapid means possible.
Putting together the brightest minds involved in basic science, drug development, medical practice and commercialization to develop new cures in the most rapid means possible.
Regen BioPharma has multiple technologies targeting various types of cancer and disorders of the immune system.
Patent Number | Patent Title | Date Granted | |||
|---|---|---|---|---|---|
US-11,324,719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | 2022-10-05 | |||
US-11,241,427-B2
| Small molecule modulators of NR2F6 Activity | 2022-02-08
| |||
US-11,141,471-B2
| Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells | 2021-10-12 | |||
US-11,090,332-B2 | Antigen specific mRNA cellular cancer vaccines | 2021-08-17 | |||
US-11,053,503-B2 | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | 2021-07-06 | |||
US-10,088,485-B2 | Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand | 2018-10-02 | |||
US-9,091,696-B2 | Modulation of NR2F6 and methods and uses thereof | 2015-07-28 | |||
US-8,389,708-B2 | Method of cancer treatment using siRNA silencing | 2013-03-05 | |||
US-8,263,571-B2 | Gene silencing of the brother of the regulator of imprinted sites (BORIS) | 2012-09-11 | |||
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
